Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study)

Hashimoto-Kameda, Reina; Cho, Kyu Yong; Nomoto, Hiroshi; Nakamura, Akinobu; Omori, Kazuno; Nagai, So; Edagawa, Sachiko; Kawata, Shinichiro; Takeuchi, Jun; Kameda, Hiraku; Kurihara, Yoshio; Aoki, Shin; Atsumi, Tatsuya; Miyoshi, Hideaki

Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study)

Hashimoto-Kameda, Reina; Cho, Kyu Yong; Nomoto, Hiroshi et al.

Diabetes research and clinical practice, 2021, 180, 109069

Permalink : https://hdl.handle.net/2115/83964

このアイテムのアクセス数:420件（2026-02-08 17:48 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1016/j.diabres.2021.109069

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	metadata only access
URI	https://hdl.handle.net/2115/83964
タイトル	Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study)
著者	Hashimoto-Kameda, Reina ; Cho, Kyu Yong ; Nomoto, Hiroshi ; Nakamura, Akinobu ; Omori, Kazuno ; Nagai, So ; Edagawa, Sachiko ; Kawata, Shinichiro ; Takeuchi, Jun ; Kameda, Hiraku ; Kurihara, Yoshio ; Aoki, Shin ; Atsumi, Tatsuya ; Miyoshi, Hideaki
著者名 Hashimoto-Kameda, Reina
著者名 Cho, Kyu Yong
著者名 Nomoto, Hiroshi
著者名 Nakamura, Akinobu
著者名 Omori, Kazuno
著者名 Nagai, So
著者名 Edagawa, Sachiko
著者名 Kawata, Shinichiro
著者名 Takeuchi, Jun
著者名 Kameda, Hiraku
著者名 Kurihara, Yoshio
著者名 Aoki, Shin
e-Rad_Researcher 20301905 著者名 Atsumi, Tatsuya
e-Rad_Researcher 30360902 著者名 Miyoshi, Hideaki
言語	英語
キーワード	inhibitor
	Type 2 diabetes
	Hypertension
	Sodium-glucose cotransporter-2
発行日	2021-10
出版者	Elsevier
収録物名	Diabetes research and clinical practice
巻(号)	180
ページ	109069
抄録	Aims: Sodium-glucose cotransporter-2 inhibitor (SGLT2i) reduces clinic blood pressure (BP), but the effects on BP circadian rhythm remain unclear. The present study aimed to determine the nighttime antihypertensive effect of SGLT2i compared with dipeptidyl peptidase-4 inhibitor (DPP-4i) in patients with type 2 diabetes and hypertension. Materials and Methods: In this randomized, open-label, parallel-group trial, patients treated with DPP-4i were either switched to luseogliflozin 2.5 mg/day (Luseo group; n = 30) or continued DPP-4i (DPP-4i group; n = 26). The patients undertook 24-h ambulatory BP monitoring before and 8 weeks after the group allocation. The primary endpoint was mean change in nighttime systolic BP (SBP). Results: Nighttime SBP, as well as daytime SBP, was significantly reduced in the Luseo group compared with the DPP-4i group (nighttime,-4.0 +/- 11.4 vs. 3.6 +/- 10.7 mmHg, P = 0.01; day time,-4.4 +/- 10.9 vs. 3.7 +/- 11.9 mmHg, P = 0.01). Similarly, nighttime pulse rate (PR) was significantly reduced in the Luseo group (-2.0 +/- 4.8 vs. 0.9 +/- 4.8 bpm, P = 0.03). The proportion of patients with abnormal BP circadian rhythms (non-dipper pattern plus riser pattern) was significantly lower in the Luseo group (36.6% vs. 56.7%, P < 0.05). Conclusions: Switching from DPP-4i to luseogliflozin decreased nighttime SBP and PR; moreover, BP circadian rhythm was improved. (C) 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
PISSN	0168-8227
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1016/j.diabres.2021.109069